Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Janus kinase (JAK) enzymes are involved in cell signaling pathways activated by various cytokines dysregulated in allergy. The objective of this study was to determine whether the novel JAK inhibitor oclacitinib could reduce the activity of cytokines implicated in canine allergic skin disease. Using...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzales, A J, Bowman, J W, Fici, G J, Zhang, M, Mann, D W, Mitton-Fry, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Scientific Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265276/
https://www.ncbi.nlm.nih.gov/pubmed/24495176
http://dx.doi.org/10.1111/jvp.12101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265276/
https://www.ncbi.nlm.nih.gov/pubmed/24495176
http://dx.doi.org/10.1111/jvp.12101

Ejemplares similares